Navigation Links
Keryx Biopharmaceuticals, Inc. Announces First Quarter 2012 Financial Results
Date:5/8/2012

statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Among the factors that could cause our actual results to differ materially are the following: our ability to successfully adjust our strategy and reduce our operating expenses following the termination of the KRX-0401 license agreement; our ability, and our Japanese partner's ability, to successfully and cost-effectively complete clinical trials for Zerenex (ferric citrate); the risk that the data (both safety and efficacy) from the ongoing Phase 3 trials for Zerenex (ferric citrate) will not coincide with the data analyses from previous clinical trials reported by the Company; our ability to meet anticipated development timelines for Zerenex due to clinical trial results, manufacturing capabilities or other factors; and other risk factors identified from time to time in our reports filed with the Securities and Exchange Commission. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available at http://www.keryx.com. The information found on our website is not incorporated by reference into this press release and is included for reference purposes only.

KERYX CONTACT:
Lauren Fischer
Director – Investor Relations
Keryx Biopharmaceuticals, Inc.
Tel: 212.531.5965
E-mail: lfischer@keryx.com

 Keryx Biopharmaceuticals, Inc.Selected Consolidated Financial Data(In Thousands, Except Share and Per Share Amounts)Statements of Operations Information (Unaudited):
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Keryx Biopharmaceuticals to Present at William Blair & Company Small-Cap Growth Stock Conference
2. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
3. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
4. Keryx Biopharmaceuticals Completes SUN-MICRO Phase 3 Pivotal Trial
5. Keryx Biopharmaceuticals Announces that the SUN-MICRO Phase 3 Clinical Trial Failed to Meet its Primary Efficacy Endpoint
6. Keryx Biopharmaceuticals Announces Termination of SUN-MACRO Phase 4 Trial
7. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
8. Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
9. Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology
10. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data on KRX-0401 (Perifosine) in Combination with Bortezomib (+/- Dexamethasone) at the 12th International Multiple Myeloma Meeting
11. Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401s Activity in the Treatment of Advanced Metastatic Renal Cell Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... SAN FRANCISCO , Oct. 22, 2014 ... fitness and health trackers for themselves and their kids, ... Mom 2014 Report: Health & Fitness Go Mobile for ... Mom® Insights Series. BabyCenter, the number 1 pregnancy and ... which found that 55 percent of moms surveyed say ...
(Date:10/22/2014)... -- A new report by Allied Market ... End user, Application and Geography) - Size, Share, Global ... Segmentation and Forecast, 2013 - 2020", considers commercial aspects ... trends tracked, it is anticipated that the market is ... registering a CAGR of 6.2% from 2014 to 2020. ...
(Date:10/22/2014)... 2014 Oramed Pharmaceuticals Inc. ... pharmaceutical company focused on the development of oral ... results from its Phase IIa clinical trial of ... treat type 1 diabetes. The trial was conducted in ... a U.S. Food and Drug Administration (FDA) Investigational ...
Breaking Medicine Technology:BabyCenter Finds Mom Ready to Live the "Measured Life" in its U.S. Mobile Mom 2014 Report: Health & Fitness Go Mobile for Moms 2BabyCenter Finds Mom Ready to Live the "Measured Life" in its U.S. Mobile Mom 2014 Report: Health & Fitness Go Mobile for Moms 3BabyCenter Finds Mom Ready to Live the "Measured Life" in its U.S. Mobile Mom 2014 Report: Health & Fitness Go Mobile for Moms 4Global Disposable Gloves Market Expected to Grow to $7.9 Billion by 2020 - Allied Market Research 2Global Disposable Gloves Market Expected to Grow to $7.9 Billion by 2020 - Allied Market Research 3Global Disposable Gloves Market Expected to Grow to $7.9 Billion by 2020 - Allied Market Research 4Oramed Pharmaceuticals Reports Positive Top-Line Data from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 2Oramed Pharmaceuticals Reports Positive Top-Line Data from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 3Oramed Pharmaceuticals Reports Positive Top-Line Data from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 4
... GeoVax Labs, Inc. (OTC BB: GOVX), an Atlanta-based, biopharmaceutical ... Immunodeficiency Virus (HIV) infections, today announced its financial results and ... 30, 2011. GeoVax reported a net loss of ... 30, 2011, compared to $933,089 ($0.06 per share) for the ...
... Spherix Incorporated (NASDAQ: SPEX ) ... metabolic syndrome and atherosclerosis, and providers of technical and ... companies – today reported financial results for the three ... Recent and Upcoming Highlights ...
Cached Medicine Technology:GeoVax Labs, Inc. Announces Second Quarter Financial Results 2GeoVax Labs, Inc. Announces Second Quarter Financial Results 3GeoVax Labs, Inc. Announces Second Quarter Financial Results 4Spherix Announces Second Quarter Financial Results 2Spherix Announces Second Quarter Financial Results 3Spherix Announces Second Quarter Financial Results 4Spherix Announces Second Quarter Financial Results 5Spherix Announces Second Quarter Financial Results 6Spherix Announces Second Quarter Financial Results 7
(Date:10/25/2014)... News) -- Interrupting blood supply to an arm or a ... with the surgery, according to a new study. ... to the heart to be able to operate on it. ... its ability to produce energy because it doesn,t get oxygen. ... muscle, such as an arm or a leg, the body ...
(Date:10/25/2014)... News) -- Current osteoporosis screening guidelines and tools ... risk for osteoporosis-related fractures, a new study says. ... need tools that help us accurately predict who ... can target these at-risk people for preventive measures," ... in the division of general internal medicine and ...
(Date:10/22/2014)... On October 22, CBS will air ... diseases both fictional and real. The Charles E ... committed to advocacy and philanthropy in the battle against ... opportunity to impart truth and clarity about this misunderstood ... many misconceptions about Morgellons Disease (MD) and ...
(Date:10/22/2014)... -- The United States is now mandating that ... West Africa land at one of five airports ... virus. In a statement released Tuesday, Homeland ... of air passengers from Guinea, Liberia and Sierra ... airports -- New York City,s Kennedy International Airport, ...
(Date:10/22/2014)... During the Western United States’ worst ... dangerously low, Southern Oregon’s water is proving resistant to ... lowest mountain snow pack on record in 2014, remain ... autumn.* That was the observation of journalist-hikers Art Bernstein ... Southern Oregon,” during an interview with water advocate Sharon ...
Breaking Medicine News(10 mins):Health News:Brief Interruption of Blood Supply to Limb Might Aid Heart Surgery: Study 2Health News:Osteoporosis Screening Guidelines May Miss Younger Women at Risk 2Health News:CBS’ Criminal Minds takes aim at skin disease with Morgellons in the Mix 2Health News:CBS’ Criminal Minds takes aim at skin disease with Morgellons in the Mix 3Health News:Passengers From Ebola-Affected Countries Must Land at Designated U.S. Airports 2Health News:Passengers From Ebola-Affected Countries Must Land at Designated U.S. Airports 3Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 2Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 3Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 4
... One year after a person is diagnosed with rheumatoid arthritis ... attack compared to people without the disease, a new study ... diagnosed with rheumatoid arthritis, a chronic autoimmune disease marked by ... than 37,000 people without the disease. The study was conducted ...
... from a large European study suggest that poorly educated people ... heart failure than the better educated, even after differences in ... online today (Thursday 9 December) in the European Heart ... as long as 31 years (range 0-31 years, average follow-up ...
... LOS ANGELES (December 8, 2010) Jeffrey S. Upperman, ... Angeles, has co-authored a call to action for filling a ... oversight to establish the framework for a pediatric applied trauma ... simultaneously in the Journal of Pediatric Surgery and ...
... kid trying to join in and be one of the ... feel included, be accepted and valued particularly by their ... children with disabilities around inclusion in physical activities during free ... physical activity expert, in the Faculty of Physical Education and ...
... HealthDay Reporter , WEDNESDAY, Dec. 8 (HealthDay News) -- Sudden infant ... a mysterious and terrifying killer of newborns. But medical researchers ... to die of SIDS, an advance that could save hundreds ... die of SIDS tend to have significantly lower amounts of serotonin ...
... , Prostate cancer is the most common type of cancer ... inaccurate and unpleasant. Researchers at Eindhoven University of Technology (TU/e), ... that can accurately identify tumors. The technology is based on ... tumors are. This can lead to better and more appropriate ...
Cached Medicine News:Health News:Study Suggests Rheumatoid Arthritis Linked to Heart Attack Risk 2Health News:Lower levels of education are associated with increased risks of heart failure 2Health News:Lower levels of education are associated with increased risks of heart failure 3Health News:Lower levels of education are associated with increased risks of heart failure 4Health News:Trauma surgeon leads call to action for pediatric applied trauma research network 2Health News:Feeling included -- kids with disabilities have their say in landmark study 2Health News:Feeling included -- kids with disabilities have their say in landmark study 3Health News:Serotonin May Be the Key to SIDS 2Health News:Serotonin May Be the Key to SIDS 3Health News:Accurate diagnosis of prostate cancer with ultrasound 2Health News:Accurate diagnosis of prostate cancer with ultrasound 3
... Bulb Direct has been ... Internet since 1996, and we ... 100% satisfaction guarantee. Check out ... and see our discount light ...
With the Symphony family of Pacemakers, Ela presents the most advanced technology on the market. Symphony, lighter than a passport, will take your patients further, offering fast follow-up, using new...
With the Symphony family of Pacemakers, Ela presents the most advanced technology on the market. Symphony, lighter than a passport, will take your patients further, offering fast follow-up, using new...
.90mm (20G) guillotine cutting probe with 1.4mm (17G) removable irrigation sleeve...
Medicine Products: